This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
Odell and his co-workers (Science109: 564, 1949; Cancer Research9:362, 1949) of the University of Chicago recently reported that the vaginal fluid showed "consistently high values for beta-glucuronidase in the presence of untreated cervical cancer" and have proposed the assay of betaglucuronidase in vaginal secretions as suited for large surveys of the population for detecting uterine cervical cancer. The selection of beta-glucuronidase as the enzyme for his study was stated to rest on the previous work of Fishman and his co-workers (Cancer Research7:808, 1947), who found in the majority of cases studied enhanced beta-glucuronidase activity in human cancer tissue (breast, esophagus, stomach, colon, lymph nodes, uterus). The physiologic function of the enzyme is not well understood, although a relationship with the action of the estrogenic hormones has been investigated (Fishman, W. H., and Fishman, L. W.: J. Biol. Chem.152:487, 1944).Odell
Fishman WH, Kasdon SC, Homburger F. PROPOSED CANCER TEST. JAMA. 1950;142(2):125. doi:10.1001/jama.1950.02910200053022
Customize your JAMA Network experience by selecting one or more topics from the list below.